AstraZeneca PLC (AZN)
185.43
+1.51
(+0.82%)
USD |
NYSE |
May 19, 10:56
AstraZeneca Research and Development Expense (Quarterly) : 3.456B for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| GSK Plc | 2.045B |
| Johnson & Johnson | 3.495B |
| Eli Lilly & Co. | 3.51B |
| Merck & Co., Inc. | 11.98B |
| Novo Nordisk A/S | 1.610B |